SCYNEXIS, Inc. SCYX 深 滬
已收盤 02-06 16:00:00 美东时间
0.759
+0.069
+9.94%
華盛通- 最 高0.78
- 今 開0.7104
- 成交量 21.32万股
- 最 低 0.7003
- 昨 收 0.6904
- 總市值 3185.15万
- 52周最高 1.31
- 市盈率 靜 --
- 換手率 0.51%
- 52周最低 0.565
- 委 比 50.00%
- 總股本 4196.51万
- 歷史最高 150.00
- 量 比 0.57
- 振 幅 11.54%
- 歷史最低 0.565
- 每 手 1
- 風險率 0.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多SCYNEXIS Announces Upcoming Presentations Highlighting Data On Second-Gen Fungerp Drug Candidate, SCY-247, At 2026 IMARI
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations highlighting data on
01-28 21:05
SCYNEXIS Granted FDA's Qualified Infectious Disease Product, Fast Track Designations For Second-Generation Triterpenoid Antifungal Therapy SCY-247
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration
01-21 21:02
SCYNEXIS Receives Nasdaq Extension To Regain Bid Price Compliance By June 15, 2026
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional
2025-12-22 21:12
Trevi Therapeutics appoints new CFO
Trevi Therapeutics (TRVI) named David Hastings as its next chief financial officer, effective January 6, 2026. Hastings prior roles include CFO positions at Arbutus, Unilife, and Incyte. Hastings curr...
2025-12-04 20:43
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 18.6% to $2.1...
2025-11-21 05:06
SCYNEXIS Completes Transfer Of BREXAFEMME New Drug Application To GSK
GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low
2025-11-19 20:09
SCYNEXIS Secures 5-Year $7M Annual Federal Grant To Advance Next-Generation Antifungal Therapies
Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company's next generation of
2025-11-17 23:17
SCYNEXIS Q3 EPS $(0.17) Beats $(0.20) Estimate, Sales $334.000K Beat $147.667K Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.20) by 15 percent. This is a 183.33 percent decrease over losses of $(0.06) per share from the same
2025-11-06 06:04
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
SCYNEXIS announced Q3 2025 financial results, highlighting a $24.8 million one-time payment from GSK to resolve the Phase 3 MARIO study disagreement. The company also shared positive SAD/MAD data for its second-generation antifungal, SCY-247, expecting to begin Phase 2 studies in 2026. GSK continues to support the relaunch of BREXAFEMME, with potential milestones and royalties for SCYNEXIS. The company ended Q3 with $37.9 million in cash, which w...
2025-11-05 21:20
美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
2025-10-29 09:25
